RxDoctor Payments Data

Christina Young, APRN

Family · Orange, CTNPI 1467852095

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.7% of the total across 503 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,850in general payments, 2019–2025

Across 503 payments — averaging $19.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$1K
  • Sanofi$885
  • Incyte Corporation$793
  • Pfizer$776
  • Amgen$681
  • plus $4K from 23 others

What the payments were for

  • Food & beverage$9,52997%
  • Education$3213%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,850 in reported general payments places this provider in the 95th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$60,870
Medicare patients
280
Services billed
1,008

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole22$22,693
Clobetasol Propionate109$4,044
Fluorouracil32$2,815
Metronidazole31$1,824
Ketoconazole122$1,605
Tacrolimus15$1,224
Doxycycline Hyclate28$925
Triamcinolone Acetonide84$886
Tretinoin14$634
Clindamycin Phosphate19$531
Mupirocin64$479
Ciclopirox13$435
Hydrocortisone31$94

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$125$22,69322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,596 family providers in Connecticut.

Other family in Orange

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →